References
- World Health Organization. Rotavirus. [accessed 2023 Sep 19]. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccines-quality/rotavirus.
- Troeger C, Khalil IA, Rao PC, Cao S, Blacker BF, Ahmed T, Armah G, Bines JE, Brewer TG, Colombara DV, et al. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr. 2018;172:958–10. doi:10.1001/jamapediatrics.2018.1960.
- Zhang J, Duan Z, Payne DC, Yen C, Pan X, Chang Z, Liu N, Ye J, Ren X, Tate JE, et al. Rotavirus-specific and overall diarrhea mortality in Chinese children younger than 5 years: 2003 to 2012. Pediatr Infect Dis J. 2015;34:e233–7. doi:10.1097/INF.0000000000000799.
- Wu D, Yen C, Yin ZD, Li YX, Liu N, Liu YM, Wang HQ, Cui FQ, Gregory CJ, Tate TE, et al. The public health burden of rotavirus disease in children younger than five years and considerations for rotavirus vaccine introduction in China. Pediatr Infect Dis J. 2016;35:392–8. doi:10.1097/INF.0000000000001327.
- World Health Organization. Rotavirus vaccines: WHO position paper – July 2021. Wkly Epidemiol Rec. 96(28):301. [accessed 2023 Sep 19]. https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers/rotavirus.
- Fu C, Tate JE, Jiang B. Effectiveness of Lanzhou lamb rotavirus vaccine against hospitalized gastroenteritis: further analysis and update. Hum Vaccin. 2010;6:953. doi:10.4161/hv.6.11.12847.
- National Medical Products Administration. List of approved domestic vaccine products in China. Rotavirus (Live) Vaccine, Oral. [accessed 2023 Sep 19]. https://www.nmpa.gov.cn/datasearch/en/search-info-en.html?nmpa=aWQ95Zu96I2v5YeG5a2XUzIwMDEwMDAyJml0ZW1JZD0yYzliYTM4MTc5ZDA4ZjRmMDE3OWQxM2NhNGY0MDA0ZQ== .
- RotaTeq. Local product circular. Shanghai: MSD China; 2018 [accessed 2024 Mar 4]. https://www.msdchina.com.cn/wp-content/uploads/2023/09/%E4%B9%90%E5%84%BF%E5%BE%B7-%E8%AF%B4%E6%98%8E%E4%B9%A6-%E8%BF%9B%E5%8F%A3semi-%E7%AE%80%E7%89%88%EF%BC%88%E6%96%B9%E6%AD%A3%E9%BB%91%EF%BC%89-23.7.26-%E6%9B%B2%E7%BA%BF.pdf .
- National Medical Products Administration. List of approved domestic vaccine products in China. Reassortant Rotavirus Vaccine, Live, Oral, Trivalent (Vero Cell). [accessed 2023 Sep 19]. https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9YjFjOWVlMTQyOGJhMzkyZTFmMTdiN2ZkYjk0M2M1ZjQmaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTg0MDg4MWY4NDgxNzlm.
- RotaTeq [prescribing information]. Rahway (NJ): Merck Sharp & Dohme LLC; 2023 Apr. [accessed 2024 Mar 7]. https://www.fda.gov/media/75718/download.
- Mo Z, Mo Y, Li M, Tao J, Yang X, Kong J, Wei D, Fu B, Liao X, Chu J, et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine. 2017;35:5897–904. doi:10.1016/j.vaccine.2017.08.081.
- Rodriguez ZM, Goveia MG, Stek JE, Dallas MJ, Boslego JW, DiNubile MJ, Heaton PM. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr Infect Dis J. 2007;26:221–7. doi:10.1097/01.inf.0000254391.71103.e8.
- Ciarlet M, Sani-Grosso R, Yuan G, Liu GF, Heaton PM, Gottesdiener KM, Arredondo JL, Schödel F. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J. 2008;27:874–80. doi:10.1097/INF.0b013e3181782780.
- Ciarlet M, He S, Lai S, Petrecz M, Yuan G, Liu GF, Mikviman E, Heaton M, Panzer F, Rose T, et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatr Infect Dis J. 2009;28:177–81. doi:10.1097/INF.0b013e31818c0161.
- Mo Z, Ma X, Luo P, Mo Y, Kaplan SS, Shou Q, Zheng M, Hille DA, Arnold BA; V260-024 Study Group, et al. Immunogenicity of pentavalent rotavirus vaccine in Chinese infants. Vaccine. 2019;37:1836–43. doi:10.1016/j.vaccine.2019.02.018.
- Vesikari T, Karvonen A, Borrow R, Kitchin N, Baudin M, Thomas S, Figuet A. Results from a randomized clinical trial of coadministration of RotaTeq, a pentavalent rotavirus vaccine, and NeisVac-C, a meningococcal serogroup C conjugate vaccine. Clin Vaccine Immunol. 2011;18:878–84. doi:10.1128/CVI.00437-10.
- World Health Organization. Position statement safety and pre-qualification of oral polio vaccine (OPV); 2006 May. [accessed 2023 Sep 19]. https://polioeradication.org/wp-content/uploads/2016/09/Position-statement_OPVsafety.pdf.
- World Health Organization. Polio vaccines: WHO position paper – March 2016. Wkly Epidemiol Rec. 2016;91(12):145. [accessed 2023 Sep 19]. https://www.who.int/publications/i/item/WHO-WER9112.
- World Health Organization. Polio eradication and endgame strategic plan 2013–2018. Geneva (Switzerland): World Health Organization; 2013. Polio Global Eradication Initiative. [accessed 2023 Sep 19]. https://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf.
- World Health Organization. Meeting of the strategic advisory group of experts on immunization, November 2012 - conclusions and recommendations. Wkly Epidemiol Rec. 2013;88:1. [accessed 2023 Sep 19]. https://apps.who.int/iris/bitstream/handle/10665/242011/WER8801_1-16.PDF?sequence=1&isAllowed=y.
- World Health Organization. Polio eradication strategy 2022–2026: delivering on a promise. Geneva (Switzerland): World Health Organization; 2021. Polio Global Eradication Initiative. [accessed 2023 Sep 19]. https://apps.who.int/iris/bitstream/handle/10665/345967/9789240031937-eng.pdf.
- World Health Organization. Poliomyelitis (polio) in China. [accessed 2023 Sep 19]. https://www.who.int/china/health-topics/poliomyelitis-(polio).
- National Health Commission of the People’s Republic of China. Childhood immunization schedule for national immunization program vaccines - China (version 2021). China CDC Wkly. 2021;3:1101–8. doi:10.46234/ccdcw2021.270.
- World Health Organization. Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (inactivated), Annex 3, TRS No 1024. Amendment to Annex 3 of the WHO Technical Report Series, No. 993; 2020 Nov 6. [accessed 2023 Sep 19]. https://www.who.int/publications/m/item/poliomyelitis-vaccines-annex-3-trs-no-1024.
- Nathanson N. David Bodian’s contribution to the development of poliovirus vaccine. Am J Epidemiol. 2005;161:207–212. doi:10.1093/aje/kwi033.
- Shin S, Anh DD, Zaman K, Yunus M, Mai le TP, Thiem VD, Azim T, Victor VC, Dallas MJ, Steele AD, et al. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Vaccine. 2012;30(suppl 1):106–13. doi:10.1016/j.vaccine.2011.11.091.
- Armah GE, Breiman RF, Tapia MD, Dallas MJ, Neuzil KM, Binka FN, Sow SO, Ojwando J, Ciarlet M, Steele AD. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine. 2012;30(suppl 1):A86–A93. doi:10.1016/j.vaccine.2011.10.006.
- Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–26. doi:10.1002/sim.4780040211.